Created through a partnership between ventilator manufacturers, including Dräger, GE Healthcare, Getinge, Hamilton Medical, Medtronic, Nihon Kohden, Philips, and other manufacturers and powered by Allego, the central the central knowledge hub provides free mobile access to video tutorials, instruction manuals, and other training materials for equipment that is critical to helping clinicians treat patients suffering from COVID-19 related respiratory distress. Manufacturers are responsible for their own content. Continue reading→

Fighting Coronavirus/COVID-19 with Public Health Data

The City of Tempe and Arizona State University are working together to study wastewater as a strategy to advance community health. Tempe is in a unique position for an innovative response to the coronavirus/COVID-19 pandemic due to the Wastewater Data Analytics – Opioids program supported by the Tempe City Council’s Innovation Fund in 2018 and the community trust cultivated by the city’s compassion, science and services approach in using public health data. Continue reading→

Rapid release of open coronavirus sequence data will help guide COVID-19 public health response, drive innovation and discovery, and advance understanding of this and future pandemics.

The SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus.  Consortium members include Northern Arizona University, TGen, and the State of Ariona.

Continue reading→

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 TreatmentContinue reading→

Continue reading→

• Collaboration goal to enable manufacturing of up to 1 billion doses per year
• Technology transfer expected to begin in June 2020
• First batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020
• Collaboration leverages Lonza’s worldwide expertise in technology transfer and manufacturing

Continue reading→

On April 29, 2020, Daniel O’Day, Chairman & CEO, Gilead Sciences shared an Open Letter following the official press release containing data on Remdesivir and COVID-19.      

“The results from the global, placebo-controlled trial run by the National Institute of Allergy and Infectious Diseases (NIAID) are positive. They show that patients with COVID-19 who received remdesivir recovered faster than similar patients who received placebo” O’Day writes.  “There is still more work to do and remdesivir has not been approved, but all of us at Gilead are humbled by what these promising results might mean for patients. After years of research and hard work on remdesivir, there is relief and gratitude among our teams today that their efforts have been so worthwhile.”

Continue reading→

Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of RemdesivirContinue reading→

PHOENIX⁠ — Governor Doug Ducey today announced an extension of physical distancing measures while laying out a step-by-step approach to continue reenergizing Arizona’s economy. The Governor today issued an Executive Order extending Arizona’s Stay Home, Stay Healthy, Stay Connected Order until May 15, 2020. 

The order also continues Arizona’s gradual economic reopening, allowing retail businesses to begin partial operations starting next week. Under the order, retail businesses currently not operating can begin curbside pick-up on Monday, May 4, followed by expanded in-person operations on Friday, May 8 as long as they implement social distancing and sanitation measures established by the United States Department of Labor or the Arizona Department of Health Services.Continue reading→

Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials.Continue reading→